Basaglar

— THERAPEUTIC CATEGORIES —
  • Diabetes

Basaglar Generic Name & Formulations

General Description

Insulin glargine (recombinant) 100 Units/mL; for SC inj; contains m-cresol.

How Supplied

KwikPen prefilled pens (3mL)—5

Manufacturer

Generic Availability

NO

Basaglar Indications

Indications

Type 1 diabetes (in adults and children) and type 2 diabetes (in adults).

Limitations of Use

Not for treating diabetic ketoacidosis.

Basaglar Dosage and Administration

Adults and Children

Give by SC inj once daily at same time each day into abdominal area, thigh, or deltoids; rotate inj sites. No pronounced peak, duration over 24hrs. <6yrs: not established. ≥6yrs: individualize; monitor and adjust as needed. Type 1 diabetes: initially ⅓ of total daily insulin dose. Give remainder of the total dose as short- or rapid-acting, premeal insulin. Type 2 diabetes: initially 0.2 Units/kg or up to 10 Units once daily. May need to adjust amount, timing of short- or rapid-acting insulins and doses of any antidiabetics. Switching from another insulin glargine 100 Units/mL product: initial Basaglar dose should be the same as previous insulin glargine 100 Units/mL dose. Switching from once-daily insulin glargine 300 Units/mL: initially 80% of the previous insulin glargine 300 Units/mL dose. Switching from an intermediate- or long-acting insulin regimen (other than insulin glargine 100 Units/mL): may need to change basal insulin dose; and adjust the amount, timing of the short-acting insulins and doses of any antidiabetics. Switching from twice-daily NPH: initially 80% of the previous total NPH dose.

Basaglar Contraindications

Contraindications

During episodes of hypoglycemia.

Basaglar Boxed Warnings

Not Applicable

Basaglar Warnings/Precautions

Warnings/Precautions

Instruct patients on proper administration of insulin, type of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients, even if the needle is changed. Visual impairment: will need assistance with prefilled pens. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyper- or hypoglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Pregnancy. Nursing mothers.

Basaglar Pharmacokinetics

See Literature

Basaglar Interactions

Interactions

Do not mix or dilute with other insulins. Potentiated by antidiabetic agents, ACEIs, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, somatostatin analogs, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, glucagon, oral contraceptives, progestogens, atypical antipsychotics, protease inhibitors. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt signs of hypoglycemia.

Basaglar Adverse Reactions

Adverse Reactions

Hypoglycemia, allergic reactions, inj site reactions, lipodystrophy, pruritus, rash, edema, weight gain; hypokalemia.

Basaglar Clinical Trials

See Literature

Basaglar Note

Not Applicable

Basaglar Patient Counseling

See Literature